Recombinant Human IL-33 Biotinylated Protein, CF

Catalog #: BT3625 Datasheet / COA / SDS

Biotinylated

Catalog #	Availability	Size / Price	Qty
BT3625-025

2 Images

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human IL-33 Biotinylated Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human ST2/IL-33R Fc Chimera (Catalog # 523-ST) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human IL-33 (Catalog # BT3625) binds with an ED₅₀ of 0.900-9.00 ng/mL.

Source

E. coli-derived human IL-33 protein
Ser112-Thr270

Accession #

O95760.1

N-terminal Sequence
Analysis

Ser112

Structure / Form

Biotinylated via amines

Predicted Molecular Mass

18 kDa

SDS-PAGE

18-22 kDa, under reducing conditions.

Product Datasheets

BT3625

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

BT3625

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS, EDTA and DTT with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Human ST2/IL-33R Fc Chimera Protein (523-ST) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human IL‑33 Protein (Catalog # BT3625) binds with an ED₅₀ of 0.900-9.00 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human IL-33 Biotinylated Protein (Catalog # BT3625) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-22 kDa.

Reconstitution Calculator

Background: IL-33

IL-33, also known as NF-HEV and DVS 27, is a 30-kDa proinflammatory protein that was identified based on sequence and structural homology with IL‑1 family cytokines (1-3). IL‑33 is constitutively expressed in smooth muscle and airway epithelia and is up-regulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL‑1 alpha or IL‑1 beta stimulation (1, 3). Similar to IL‑1, IL‑33 can be cleaved in vitro by caspase‑1, generating an N‑terminal fragment that is slightly shorter than the C‑terminal fragment (3, 4). The N‑terminal portion of full-length IL‑33 contains a predicted bipartite nuclear localization sequence and a homeodomain‑like helix‑turn‑helix DNA binding domain. By immunofluorescence, full-length IL‑33 localizes to the nucleus in HUVECs and transfectants (2). The C‑terminal fragment, corresponding to mature IL‑33, binds and triggers signaling through mast cell IL‑1 R4/ST2L, a longtime orphan receptor involved in the augmentation of Th2 cell responses (3, 5‑7). A ternary signaling complex is formed by the subsequent association of IL‑33 and ST2L with IL‑1R AcP (8). Stimulation of Th2 polarized lymphocytes with mature IL‑33 in vitro induces IL‑5 and IL‑13 secretion (3). In vivo administration of mature IL‑33 promotes increased production of IL‑5, IL‑13, IgE, and IgA, as well as splenomegaly and inflammatory infiltration of mucosal tissues (3). Mature human IL‑33 shares 52‑58% aa sequence identity with mouse and rat IL‑33 and shares less than 20% aa sequence identity with other IL‑1 family proteins.

References

Onda, H. et al. (1999) J. Cereb. Blood Flow Metab. 19:1279.
Baekkevold, E.S. et al. (2003) Am. J. Pathol. 163:69.
Schmitz, J. et al. (2005) Immunity 23:479.
Black, R.A. et al. (1989) J. Biol. Chem. 264:5323.
Xu, D. et al. (1998) J. Exp. Med. 187:787.
Lohning, M. et al. (1998) Proc. Natl. Acad. Sci. 95:6930.
Dinarello, C.A. (2005) Immunity 23:461.
Chackerian, A.A. et al. (2007) J. Immunol. 179:2551.

Long Name

Interleukin 33

Entrez Gene IDs

90865 (Human); 77125 (Mouse)

Alternate Names

C9orf26; C9orf26chromosome 9 open reading frame 26 (NF-HEV); DKFZp586H0523; DVS27; DVS27-related protein; IL1F11; IL-1F11; IL33; IL-33; interleukin 33; Interleukin-1 family member 11; interleukin-33; NFHEV; NF-HEV; NF-HEVNFEHEV; Nuclear factor from high endothelial venules; RP11-575C20.2